SPAC Deal for 8i and EUDA Health

by | Apr 12, 2022

SPAC Deal for 8i Acquisition 2 Corp. (LAX) and EUDA Health. A look at upcoming merger and extension votes. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

SPAC Deal: 8i Acquisition 2 Corp. (LAX) + EUDA Health

8i Acquisition 2 Corp.(LAX) announced a definitive agreement to merge with  Singapore-based digital health platform EUDA Health. The deal values EUDA Health at an enterprise value of $673M. No PIPE. Cash proceeds raised will consist of 8i’s approximately $86.3 million of cash in trust (before redemptions). Additional earnouts in the form of 9 million total shares will be awarded post-transaction close if EUDA’s share price reaches $15, $20 and $25 over three years. Slide deck here.

L&F Acquisition Corporation I (LNFA) Extends

L&F Acquisition Corp. (LNFA) sets 5/3 extension vote (out to August). $10.15 in trust. The SPAC has a pending deal announcement with ZeroFox since Dec.

Elsewhere in SPACs

Upcoming Merger and Extension Votes

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Daily SPAC Update – September 17, 2024

PLMI DeSPACs to VEEA. CHEB and SHPO SPAC Deals Announced. OAKU Sets Extension Vote. Prospect Energy Holdings Pulls SPAC IPO. AOGO Delists. Zalatoris II Redemption Update. NBST Trust Update.

Daily SPAC Update – September 16, 2024

Alpha Star Acquisition + OU XData Group SPAC Deal. GATE Extension Approved. FIAC Deal Approved. NNAG Liquidation. NBST Extension Vote Set. BAYA and ROSS Extension Votes.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.